Everest Medicines Limited
HKEX:1952.HK
33.3 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 125.932 | 12.792 | 0.054 | 0 | 0 | 0 |
| Cost of Revenue
| 34.414 | 4.645 | 0.023 | 0 | 0 | 0 |
| Gross Profit
| 91.518 | 8.147 | 0.031 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.727 | 0.637 | 0.574 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 540.054 | 809.736 | 613.433 | 377.411 | 150.888 | 55.911 |
| General & Administrative Expenses
| 165.155 | 276.547 | 242.676 | 277.833 | 34.058 | 26.558 |
| Selling & Marketing Expenses
| 231.419 | 326.687 | 198.15 | 33.246 | 0 | 0 |
| SG&A
| 396.574 | 603.234 | 440.826 | 311.079 | 34.058 | 26.558 |
| Other Expenses
| -19.331 | -4.624 | -4.956 | -1.084 | 13.582 | -863.219 |
| Operating Expenses
| 923.453 | 1,408.346 | 1,049.303 | 687.406 | 198.528 | 126.998 |
| Operating Income
| -932.738 | -1,400.199 | -1,049.272 | -688.457 | -176.112 | -127.182 |
| Operating Income Ratio
| -7.407 | -109.459 | -19,430.963 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 6.803 | 1,152.924 | 40.553 | -4,969.708 | -38.4 | -864.676 |
| Income Before Tax
| -844.463 | -247.275 | -1,008.719 | -5,658.165 | -214.512 | -991.674 |
| Income Before Tax Ratio
| -6.706 | -19.33 | -18,679.981 | 0 | 0 | 0 |
| Income Tax Expense
| 79.593 | 0.008 | 4.816 | 23.82 | -21.04 | -863.328 |
| Net Income
| -844.463 | -247.283 | -1,013.535 | -5,681.985 | -193.472 | -991.674 |
| Net Income Ratio
| -6.706 | -19.331 | -18,769.167 | 0 | 0 | 0 |
| EPS
| -2.7 | -0.83 | -3.46 | -26.46 | -0.68 | -3.5 |
| EPS Diluted
| -2.7 | -0.83 | -3.46 | -26.46 | -0.68 | -3.5 |
| EBITDA
| -694.897 | -1,478.632 | -972.779 | -5,613.95 | -225.548 | -985.209 |
| EBITDA Ratio
| -5.518 | -115.59 | -18,014.426 | 0 | 0 | 0 |